

SUPPLEMENTARY MATERIAL

eFigure 1. Course of the levels of the biological inflammatory markers LCRP (A), NLR (B) and IL-6 (C) during the visit according to hydroxyzine daily dose. Vertical lines represent standard errors.





Figure 2. Quantitative bias analysis based on the observed residual differences in age (A) and other patients characteristics (B).



eTable 1. Associations of baseline clinical characteristics with the endpoint of death in the cohort of patients who had been admitted to the hospital for Covid-19 (N=7,345).

| | Full population (N=7,345) | With the end- point event (N=994) | Without the end-point event (N=6,351) | Endpoint of death | | Collinearity diagnosis (GVIF ^{1/(2*df)}) |
|--|------------------------------|---|---|------------------------|--------------------------------|---|
| | | | | Crude analysis | Multivariable analysis (df=20) | |
| | N (%) | N (%) | N (%) | HR (SE) / p-value | HR (SE) / p-value | |
| Age | | | | | | 1.06 |
| 18 to 50 years | 2709 (36.9%) | 42 (4.23%) | 2667 (42.0%) | Ref. | Ref. | |
| 51 to 70 years | 2530 (34.4%) | 240 (24.1%) | 2290 (36.1%) | 5.31 (0.17) / <0.001* | 2.82 (0.20) / <0.001 | |
| 71 to 80 years | 942 (12.8%) | 273 (27.5%) | 669 (10.5%) | 14.86 (0.17) / <0.001* | 7.53 (0.20) / <0.001 | |
| More than 80 years | 1164 (15.8%) | 439 (44.2%) | 725 (11.4%) | 16.99 (0.16) / <0.001* | 11.35 (0.19) / <0.001 | |
| Sex | | | | | | 1.06 |
| Women | 3619 (49.3%) | 359 (36.1%) | 3260 (51.3%) | Ref. | Ref. | |
| Men | 3726 (50.7%) | 635 (63.9%) | 3091 (48.7%) | 1.68 (0.07) / <0.001* | 1.32 (0.08) / <0.001 | |
| Obesity ^a | | | | | | 1.06 |
| Yes | 975 (13.3%) | 216 (21.7%) | 759 (12.0%) | 1.51 (0.08) / <0.001* | 1.23 (0.09) / 0.021 | |
| No | 6370 (86.7%) | 778 (78.3%) | 5592 (88.0%) | Ref. | Ref. | |
| Smoking ^b | | | | | | 1.03 |
| Yes | 623 (8.48%) | 149 (15.0%) | 474 (7.46%) | 1.51 (0.09) / <0.001* | 0.93 (0.10) / 0.452 | |
| No | 6722 (91.5%) | 845 (85.0%) | 5877 (92.5%) | Ref. | Ref. | |
| Number of medical conditions ^γ | | | | | | 1.12 |
| 0 | 4750 (64.7%) | 319 (32.1%) | 4431 (69.8%) | Ref. | Ref. | |
| 1 | 534 (7.27%) | 63 (6.34%) | 471 (7.42%) | 2.29 (0.14) / <0.001* | 1.78 (0.16) / <0.001 | |
| 2 or more | 2061 (28.1%) | 612 (61.6%) | 1449 (22.8%) | 4.71 (0.07) / <0.001* | 3.49 (0.09) / <0.001 | |

| | | | | | | |
|---|--------------|-------------|--------------|-----------------------|----------------------|------|
| Medication according to compassionate use or as part of a clinical trial ^θ | | | | | | 1.11 |
| <i>Yes</i> | 1288 (17.5%) | 226 (22.7%) | 1062 (16.7%) | 1.13 (0.08) / 0.105 | 0.74 (0.09) / 0.001 | |
| <i>No</i> | 6057 (82.5%) | 768 (77.3%) | 5289 (83.3%) | Ref. | Ref. | |
| Anxiety or insomnia ^ε | | | | | | 1.04 |
| <i>Yes</i> | 299 (4.07%) | 101 (10.2%) | 198 (3.12%) | 2.38 (0.11) / <0.001* | 1.24 (0.12) / 0.062 | |
| <i>No</i> | 7046 (95.9%) | 893 (89.8%) | 6153 (96.9%) | Ref. | Ref. | |
| Any other antihistamine medication | | | | | | 1.01 |
| <i>Yes</i> | 100 (1.4%) | 16 (1.6%) | 84 (1.3%) | 0.94 (0.25) / 0.799 | 0.67 (0.29) / 0.160 | |
| <i>No</i> | 7245 (98.6%) | 978 (98.4%) | 6267 (98.7%) | Ref. | Ref. | |
| SSRI or SNRI | | | | | | 1.08 |
| <i>Yes</i> | 318 (4.3%) | 81 (8.15%) | 237 (3.73%) | 1.5 (0.12) / <0.001* | 0.66 (0.12) / 0.001 | |
| <i>No</i> | 7027 (95.7%) | 913 (91.9%) | 6114 (96.3%) | Ref. | Ref. | |
| Any other antidepressant | | | | | | 1.05 |
| <i>Yes</i> | 142 (1.93%) | 47 (4.73%) | 95 (1.50%) | 2.03 (0.15) <0.001* | 0.85 (0.17) / 0.340 | |
| <i>No</i> | 7203 (98.1%) | 947 (95.3%) | 6256 (98.5%) | Ref. | Ref. | |
| Any mood stabilizer medication ^Ω | | | | | | 1.05 |
| <i>Yes</i> | 287 (3.91%) | 69 (6.94%) | 218 (3.43%) | 1.42 (0.12) / 0.005* | 0.93 (0.14) / 0.587 | |
| <i>No</i> | 7058 (96.1%) | 925 (93.1%) | 6133 (96.6%) | Ref. | Ref. | |
| Any benzodiazepine or Z- drug | | | | | | 1.14 |
| <i>Yes</i> | 752 (10.2%) | 268 (27.0%) | 484 (7.62%) | 2.53 (0.07) / <0.001* | 1.56 (0.09) / <0.001 | |
| <i>No</i> | 6593 (89.8%) | 726 (73.0%) | 5867 (92.4%) | Ref. | Ref. | |
| Any antipsychotic | | | | | | 1.07 |

| | | | | | |
|---|--------------|-------------|--------------|-----------------------|----------------------|
| <i>Yes</i> | 264 (3.59%) | 60 (6.04%) | 204 (3.21%) | 1.26 (0.13) / 0.086 | 0.80 (0.14) / 0.120 |
| <i>No</i> | 7081 (96.4%) | 934 (94.0%) | 6147 (96.8%) | Ref. | Ref. |
| Clinical severity of Covid-19 at admission ^u | | | | | |
| <i>Yes</i> | 1564 (21.3%) | 421 (42.4%) | 1143 (18.0%) | 1.81 (0.08) / <0.001* | 1.69 (0.09) / <0.001 |
| <i>No</i> | 1858 (25.3%) | 265 (26.7%) | 1593 (25.1%) | Ref. | Ref. |
| <i>Missing</i> | 3923 (53.4%) | 308 (31.0%) | 3615 (56.9%) | 0.59 (0.08) / <0.001* | 1.66 (0.11) / <0.001 |
| Biological severity of Covid-19 at admission ^k | | | | | |
| <i>Yes</i> | 2439 (33.2%) | 592 (59.6%) | 1847 (29.1%) | 1.94 (0.08) / <0.001* | 1.51 (0.09) / <0.001 |
| <i>No</i> | 1861 (25.3%) | 257 (25.9%) | 1604 (25.3%) | Ref. | Ref. |
| <i>Missing</i> | 3045 (41.5%) | 145 (14.6%) | 2900 (45.7%) | 0.39 (0.1) / <0.001* | 0.75 (0.12) / 0.022 |

^a Defined as having a body-mass index higher than 30 kg/m² or an International Statistical Classification of Diseases and Related Health Problems (ICD-10) diagnosis code for obesity (E66.0, E66.1, E66.2, E66.8, E66.9).

^b Smoking status was self-reported.

^v Assessed using ICD-10 diagnosis codes for diabetes mellitus (E11), diseases of the circulatory system (I00-I99), diseases of the respiratory system (J00-J99), neoplasms (C00-D49), diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism (D5-D8), delirium (F05, R41) and dementia (G30, G31, F01-F03).

^o Any medication prescribed as part of a clinical trial or according to compassionate use (e.g., hydroxychloroquine, azithromycin, remdesivir, tocilizumab, sarilumab or dexamethasone).

^e Assessed using ICD-10 diagnosis codes for anxiety, dissociative, stress-related, somatoform and other nonpsychotic mental disorders (F40-F48) and insomnia (G47).

^Ω Included lithium or antiepileptic medications with mood stabilizing properties.

^u Defined as having at least one of the following criteria: respiratory rate > 24 breaths/min or < 12 breaths/min, resting peripheral capillary oxygen saturation in ambient air < 90%, temperature > 40°C, or systolic blood pressure < 100 mm Hg.

^k Defined as having at least one of the following criteria: high neutrophil-to-lymphocyte ratio, low lymphocyte-to-C-reactive protein (both variables were dichotomized at the median of the values observed in the full sample), and plasma lactate levels higher than 2 mmol/L.

* p-value is significant (p<0.05).

Abbreviations: HR, hazard ratio; SE, standard error; GVIF, generalized variance inflation factor.

eTable 2. Association between hydroxyzine use within the 3 months prior to hospital admission and not during the visit for COVID-19 and the endpoint of death in the full sample and in the matched analytic sample.

| | Number of events / Number of patients | Crude Cox regression analysis | Multivariable Cox regression analysis | Analysis weighted by inverse-probability- weighting weights | Number of events / Number of patients | Univariate Cox regression in matched analytic samples |
|--|--|----------------------------------|--|---|---|--|
| | N (%) | HR (95% CI; p-value) | HR (95% CI; p-value) (df=23) | HR (95% CI; p-value) | N (%) | HR (95% CI; p-value) |
| Hydroxyzine use during the visit for COVID-19 | 12 / 125 (9.6%) | Ref. | Ref. | Ref. | 12 / 125 (9.6%) | Ref. |
| Hydroxyzine only within the last 3 months prior to the visit | 19 / 51 (37.3%) | 3.25 (1.58 - 6.71; 0.001*) | 3.43 (1.65 – 7.12; 0.001*) | 3.28 (1.54 – 6.98; 0.002*) | 19 / 51 (37.3%) | 3.02 (1.46 – 6.24; 0.003*) |
| Hydroxyzine use within the last 3 months and during the visit | 3 / 13 (23.1%) | 2.07 (0.59 – 7.36; 0.258) | 2.88 (0.80 – 10.30; 0.104) | 2.05 (0.57 – 7.46; 0.274) | 3 / 13 (23.1%) | 1.85 (0.52 – 6.59; 0.340) |
| No hydroxyzine | 960 / 7,156 (13.4%) | 1.84 (1.04 – 3.25; 0.036*) | 2.60 (1.47 – 4.63; 0.001*) | 3.02 (1.68 – 5.42; <0.001*) | 42 / 189 (22.2%) | 2.94 (1.55 – 5.59; 0.001*) |

* p-value is significant (p<0.05).

eTable 3. Comparing the associations of hydroxyzine use and zopiclone use with the endpoint of death in the full sample and in the matched analytic sample.

| | Number of events / Number of patients | Crude Cox regression analysis | Multivariable Cox regression analysis | Analysis weighted by inverse- probability- weighting weights | Number of events / Number of patients | Univariate Cox regression in the matched analytic sample (1:1) |
|--------------------------------|--|----------------------------------|--|---|---|---|
| | N (%) | HR (95% CI; p- value) | HR (95% CI; p- value) (df=24) | HR (95% CI; p- value) | N (%) | HR (95% CI; p- value) |
| Zopiclone | 46 / 151 (30.5%) | Ref. | Ref. | Ref. | 4 / 12 (33.3%) | Ref. |
| Hydroxyzine | 14 / 129 (10.9%) | 0.38 (0.21 - 0.70; 0.002*) | 0.39 (0.21 – 0.73; 0.003*) | 0.32 (0.15 – 0.70; 0.004*) | 14 / 129 (10.9%) | 0.27 (0.09 – 0.83; 0.022*) |
| Hydroxyzine and Zopiclone | 1 / 9 (1.1%) | 0.27 (0.04 - 2.00; 0.201) | 0.29 (0.04 – 2.43; 0.255) | 0.06 (0.01 – 0.49; 0.009*) | 1 / 9 (1.1%) | 0.19 (0.02 – 1.68; 0.135) |
| No hydroxyzine or Zopiclone | 933 / 7056 (13.2%) | 0.61 (0.045 - 0.82; 0.001*) | 0.85 (0.62 – 1.16; 0.305) | 0.74 (0.51 – 1.08; 0.116) | 49 / 264 (18.6%) | 0.61 (0.22 – 1.70; 0.349) |

* p-value is significant (p<0.05).

eTable 4. Associations between hydroxyzine daily dose and the endpoint of death among patients using hydroxyzine during the visit (N=138).

| | Number of events / Number of patients | Crude Cox regression analysis | Cox regression adjusted for age and sex | Multivariable Cox regression analysis |
|--------------------------|--|--|--|--|
| | N (%) | HR (95% CI; p-value) | HR (95% CI; p-value) (df=6) | HR (95% CI; p-value) (df=22) |
| <i>Daily dose</i> | | | | |
| Lower doses | 8 / 53 (15.1%) | Ref. | Ref. | Ref. |
| Higher doses | 2 / 53 (3.8%) | 0.11 (0.02 – 0.48; 0.004*) | 0.12 (0.03 – 0.57; 0.007*) | 0.10 (0.02 – 0.45; 0.003*) |

* p-value is significant (p<0.05).

Because daily dose could not be ascertained with certainty in 32 (23.2%) patients, these patients have been excluded from this analysis.

The variable ‘daily dose’ has been dichotomized by the median.

eTable 5. Association between levels of the biological inflammatory markers NLR, LCRP, IL-6 and lactates and the endpoint of death in the subsamples of patients with COVID-19 who had at least two measures of each marker during the visit.

| | First measure | | Last measure | |
|--|--|---|--|---|
| | Number of events / Number of patients | Crude Cox regression analysis ^a | Number of events / Number of patients | Crude Cox regression analysis ^a |
| | Events / N (%) | HR (95% CI; p-value) | Events / N (%) | HR (95% CI; p-value) |
| Biological inflammatory markers | | | | |
| LCRP | 426 / 1,879 (22.7%) | 0.83 (0.76 - 0.90; <0.001*) | 423 / 1,876 (22.5%) | 0.47 (0.43 - 0.60; <0.001*) |
| NLR | 492 / 2,158 (22.8%) | 1.26 (1.11 - 1.43; <0.001*) | 493 / 2,159 (22.8%) | 2.71 (2.47 - 2.96; <0.001*) |
| IL-6 | 53 / 315 (16.8%) | 1.29 (1.06 - 1.57; 0.010*) | 53 / 3,15 (16.8%) | 1.53 (1.33 - 1.76; <0.001*) |
| Lactates | 319 / 1,159 (27.5%) | 1.27 (0.79 – 2.03; 0.326) | 823 / 1,163 (27.8%) | 2.75 (2.43 – 3.13; <0.001*) |

^a Values were log-transformed to address non-normal distribution of the biological variables.

eTable 6. Course of the levels of the biological inflammatory markers NLR, LCRP, IL-6 and lactates during the visit according to hydroxyzine use.

| | Full population | Exposed to hydroxyzine | Not exposed to hydroxyzine | Two-way ANOVA: Interaction term |
|--|---------------------------|-------------------------------|-----------------------------------|--|
| | N / Mean (SD) | N / Mean (SD) | N / Mean (SD) | F (p) ^α |
| Biological inflammatory markers | | | | |
| LCRP | | | | 16.33 (<0.001*) |
| <i>First measurement</i> | 1,879 / 695.1 (2,732.0) | 63 / 308.4 (666.3) | 1,816 / 708.5 (2,775.3) | |
| <i>Last measurement</i> | 1,879 / 1,396.2 (3,831.7) | 63 / 1,640.5 (2,673.9) | 1,816 / 1,387.7 (3,865.9) | |
| NLR | | | | 14.80 (<0.001*) |
| <i>First measurement</i> | 2,161 / 7.1 (6.8) | 72 / 8.3 (6.8) | 2,089 / 7.1 (6.8) | |
| <i>Last measurement</i> | 2,161 / 6.8 (9.1) | 72 / 4.9 (5.8) | 2,089 / 6.8 (9.2) | |
| IL-6 | | | | 5.87 (0.016*) |
| <i>First measurement</i> | 315 / 182.4 (405.7) | 10/ 216.2 (230.1) | 305 / 181.2 (410.4) | |
| <i>Last measurement</i> | 315 / 238.1 (800.2) | 10 / 51.9 (68.6) | 305 / 244.2 (812.4) | |
| Lactates | | | | 0.94 (0.333) |
| <i>First measurement</i> | 1,142 / 1.5 (0.8) | 43 / 1.4 (0.7) | 1,099 / 1.5 (0.8) | |
| <i>Last measurement</i> | 1,142 / 1.5 (1.3) | 43 / 1.2 (0.5) | 1,099 / 1.6 (1.3) | |

^α Values were log-transformed to address non-normal distribution of the biological variables.

* p-value is significant (p<0.05).

eTable 7. Course of the levels of the biological inflammatory markers NLR, LCRP, and IL-6 during the visit according to hydroxyzine dose.

| | Full population | Low dosage | High dosage | Two-way ANOVA: Interaction term |
|--|------------------------|----------------------|------------------------|--|
| | N / Mean (SD) | N / Mean (SD) | N / Mean (SD) | F (p) ^a |
| Biological inflammatory markers | | | | |
| LCRP | | | | 4.57 (0.037*) |
| <i>First measurement</i> | 55 / 329.2 (708.6) | 25 / 273.5 (399.4) | 30 / 375.6 (893.4) | |
| <i>Last measurement</i> | 55 / 1,423.8 (2,016.8) | 25 / 957.2 (1,728.3) | 30 / 1,812.7 (2,181.2) | |
| NLR | | | | 5.62 (0.021*) |
| <i>First measurement</i> | 60 / 8.6 (7.2) | 26 / 6.3 (4.1) | 34 / 10.4 (8.4) | |
| <i>Last measurement</i> | 60 / 4.6 (5.0) | 26 / 5.7 (7.0) | 34 / 3.8 (2.6) | |
| IL-6 | | | | 0.62 (0.454) |
| <i>First measurement</i> | 10 / 216.2 (230.1) | 5 / 95.5 (148.4) | 337.0 (246.3) | |
| <i>Last measurement</i> | 10 / 51.9 (68.6) | 5 / 35.5 (52.3) | 68.4 (84.7) | |

^a Values were log-transformed to address non-normal distribution of the biological variables.

* p-value is significant (p<0.05).